A groundbreaking discovery in the field of virology could revolutionize the treatment of Cytomegalovirus (CMV), a common yet often overlooked pathogen. CMV, a pervasive virus with global infection rates exceeding 80%, poses significant risks to vulnerable populations, including those with compromised immune systems.
The virus, which spreads through body fluids and persists in the body for life, has proven challenging to treat due to its ability to evade the immune system. However, a team of researchers has developed a novel antibody with a modified structure that can outsmart CMV and neutralize its immune-evading capabilities.
"Our engineered antibodies are like a lock that the virus can't pick," says Jennifer Maynard, a professor at the University of Texas at Austin. "They retain their ability to activate the immune system but are no longer vulnerable to the virus's tricks."
The research, published in Cell, highlights a paradigm shift in antiviral therapies. Instead of solely targeting the virus, the team focused on empowering the immune system to clear infected cells. This approach, which has shown promise in experiments, could lead to more effective and safer treatments for CMV.
"It's like a tug-of-war between the virus and the immune system," explains Ahlam N. Qerqez, lead author of the study. "The virus has evolved clever strategies to pull antibodies away from their intended targets, making it harder for the immune system to do its job."
The virus produces special proteins called viral Fc receptors (vFcγRs) that interfere with the body's natural defense mechanisms. These proteins bind to antibodies and prevent them from activating immune cells, rendering them ineffective. The engineered antibodies are designed to avoid these vFcγRs while still activating natural killer (NK) cells to attack infected cells.
The team focused on a specific type of antibody called IgG1, which plays a key role in fighting infections. By studying how CMV interacts with IgG1, the researchers identified the exact regions of the antibody that the virus targets and altered them to prevent the virus from binding.
While CMV is typically dormant and symptom-free in healthy individuals, it can lead to severe complications in people with weakened immune systems, such as organ transplant recipients, cancer patients, and newborns. The virus is also the leading infectious cause of congenital birth defects, affecting up to 2% of pregnancies worldwide.
The antibody engineering techniques developed by the team could be applied to other viruses that use similar immune evasion strategies, such as other herpesviruses and even certain bacterial infections. Additionally, the findings highlight the importance of targeting infected cells—not just the virus itself—in developing effective treatments.
"This work represents a paradigm shift in how we think about antiviral therapies," says Jason McLellan, a professor at the University of Texas at Austin. "Instead of just trying to neutralize the virus, we're focusing on empowering the immune system to clear infected cells. It's a more holistic approach that could lead to better patient outcomes."
The engineered proteins will require several more rounds of testing before they can be used in clinical settings. The team is also investigating combining their approach with other therapies, such as antiviral drugs or vaccines, to create a comprehensive treatment strategy. Additional team members are from UT Austin, Cardiff University's School of Medicine, and the University of Freiburg.
